LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial

Purpose In patients with advanced lung adenocarcinoma, the impact of LKB1 mutations on cytotoxic chemotherapy efficacy remains poorly explored. Here, we aimed at investigating the potential impact of LKB1 mutational status on chemotherapy efficacy in advanced non-small-cell lung cancer (NSCLC) patie...

Full description

Bibliographic Details
Main Authors: Adele Busico, Valter Torri, Giulia Galli, Giuseppe Lo Russo, Claudia Proto, Monica Ganzinelli, Claudio Vernieri, Diego Signorelli, Eliana Rulli, Gabriella Farina, Anna Cecilia Bettini, Claudia Bareggi, Lorenzo Rosso, Massimo Moro, Stefano Indraccolo, Gabriella Sozzi, Mirko Marabese, Broggini Massimo, Marina C. Garassino
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/5/3/e000748.full

Similar Items

Similar Items